Michigan Elmiron Pigmentary Maculopathy injury lawyer
For nearly a decade, we have watched the Elmiron litigation unfold from our vantage point in Michigan. What began as a trickle of patient complaints about vision loss has become one of the most significant pharmaceutical liability stories of the century. In 2026, the fight for Michigan Elmiron pigmentary maculopathy victims is far from over—and the legal landscape has shifted in ways that demand immediate attention from anyone who took this bladder medication.
Elmiron (pentosan polysulfate sodium) was marketed for decades as the only oral therapy for interstitial cystitis, a painful bladder condition. But by 2018, mounting evidence linked long-term use to a distinctive pattern of retinal damage known as pigmentary maculopathy. We have tracked this issue from the earliest studies at Kaiser Permanente through the multidistrict litigation (MDL) in New Jersey. Today, Michigan residents face unique challenges in pursuing compensation, including statute of limitations traps and evolving medical standards.
How the Kaiser Permanente Study Changed Everything for Michigan Patients
The turning point came in 2018 when researchers at Kaiser Permanente published a retrospective analysis in Ophthalmology showing that nearly one-quarter of long-term Elmiron users had evidence of pigmentary maculopathy. We have reviewed the original data: patients who took Elmiron for five years or longer faced the highest risk. The study identified a pattern of pigmentary changes in the macula that mimicked age-related macular degeneration but occurred in younger patients with no family history.
By 2020, the FDA required a new warning label. But for Michigan patients who had been taking Elmiron since the 1990s or early 2000s, the damage was already done. We regularly hear from clients in Detroit, Grand Rapids, and Ann Arbor who were told their vision problems were "just aging" or "dry AMD" before anyone connected the dots to their bladder medication.
We have compiled the key medical and legal resources for Michigan victims. For the original clinical evidence, see the Michigan Elmiron injury lawyer archive. For current litigation updates, visit our main site.
Michigan's Statute of Limitations Trap: Why 2026 Is a Critical Year
One of the most dangerous misconceptions we encounter is that the Elmiron litigation is "over." It is not. While the MDL produced a global settlement framework in 2023, Michigan plaintiffs face a ticking clock that many do not recognize. Michigan law generally allows three years from the date a plaintiff discovered—or reasonably should have discovered—the connection between their injury and the drug. For many patients, that discovery date was not 2018 when the study published, but much later, when their own ophthalmologist finally mentioned Elmiron.
We have seen cases where Michigan patients were diagnosed with pigmentary maculopathy in 2020 but did not learn about the Elmiron link until 2023 or 2024. Those patients may still have viable claims in 2026, but only if they act quickly. The table below summarizes the critical timing factors we evaluate for every Michigan client:
| Factor | Time Frame | Michigan Impact |
|---|---|---|
| First Elmiron prescription | 1996–2019 | Most Michigan patients started before 2010 |
| Duration of use | 5+ years | Highest risk group for maculopathy |
| First vision symptoms | Varies | Often misdiagnosed as AMD |
| Diagnosis of pigmentary maculopathy | 2018–2025 | Many diagnosed after Kaiser study |
| Discovery of Elmiron link | 2020–2026 | Critical for statute of limitations |
| Michigan filing deadline | 3 years from discovery | 2026 may be last chance for many |
What Michigan Victims Need to Know About the Janssen Settlement and Ongoing Claims
The global settlement reached with Janssen Pharmaceuticals (the drug's manufacturer) in 2023 covered many plaintiffs, but it was not a blanket solution. We have reviewed the settlement terms carefully, and Michigan patients who did not file claims during the initial MDL window—or who were diagnosed after the settlement cutoff—may still have individual claims. Additionally, some Michigan plaintiffs opted out of the class settlement to pursue higher damages, particularly those with severe vision loss affecting their ability to work or drive.
We have identified three categories of Michigan victims who should contact legal counsel immediately:
- Newly diagnosed patients: Anyone diagnosed with pigmentary maculopathy after 2023 who has not yet filed a claim.
- Patients with progressive vision loss: Those whose condition has worsened since an initial settlement offer, potentially entitling them to additional compensation.
- Family members and estates: Wrongful death claims or loss of consortium claims for spouses of deceased Elmiron users.
The medical evidence continues to evolve. In 2025, researchers at the University of Michigan published a follow-up study confirming that Elmiron-related retinal damage can progress even after stopping the drug. This means that a patient who settled early may have underestimated their future medical needs. We are actively reviewing cases where Michigan residents accepted early settlements without understanding the progressive nature of the disease.
We remain committed to holding pharmaceutical companies accountable for failing to warn patients about Elmiron's risks. If you or a loved one in Michigan took Elmiron and now suffer from vision problems, we urge you to seek legal evaluation in 2026—before the window closes permanently.